Research & Articles - South Africa OLD
Science, Research & Development

Cells obtain energy during cellular respiration by oxidizing food molecules such as glucose. The energy derived from these actions is used to form ATP.

Oxidation can be defined as the removal of hydrogens from a molecule. Since a hydrogen consists of a proton and an electron, a proton and an electron are removed during oxidation.

Whenever a molecule is oxidized, another molecule must be reduced. Hydrogen is added to it. During an oxidation-reduction reaction in the cell, an enzyme is involved in transferring the hydrogen (proton + electron) to a co-enzyme, called NAD+. This enzyme has a binding site for both the substrate and NAD+.

Once both are bound with the enzyme, the hydrogen is transferred from the substrate to the NAD+. In other words, the substrate is oxidized by losing the hydrogen, and the NAD+ is reduced to NADH.

As with all enzyme-mediated reactions, once the reaction is complete, the products separate from the enzyme and the enzyme can then be used again. NADH, a high-energy electron carrier, diffuses away and is available to donate the hydrogen to other molecules.

Make the superior choice for your NAD+ treatment

For over 30 years, our expert South African Research & Development team have pioneered NAD+ for cellular optimisation, anti ageing and detox & recovery treatments.

In collaboration with Alcin Pty Ltd SA, we produce the purest NAD+ products available on the market in our state-of-the-art GMP and FDA-approved production facilities, under stringent, FDA-approved compliance and testing procedures. With Alcin Pty Ltd, we produce and deliver in excess of 12,000 NAD+ IV treatments annually – with no known side-effects.

Today, we continue to look for ways in which this amazing molecule can be used to benefit people all over the world.

Anti Ageing Researchers link NAD+ to longevity

Scientists have discovered that many chronic conditions actually begin in cells that aren't metabolising effectively – in other words, these diseases have a mitochondrial basis, with more and more being identified with this cause since the 1970s. Many of them have been successfully treated with NAD+ IV Therapy.

At age 40, levels of NAD+ have declined by 50%. This jumps to 80% by age 60. We also know that NAD+ can help protect us from free radicals – unstable atoms that influence ageing and disease – so boosting your levels of NAD+ needs to be a top priority in looking and feeling good.

NAD+ and Chronic Fatigue Syndrome

For the last few decades, Doctors have successfully treated Chronic Fatigue Syndrome, and many other diseases, with NAD+. It may also delay the ageing process and onset of other diseases, including:

  • High blood pressure
  • Depression
  • Alzheimer’s
  • Parkinson’s
  • Diabetes

NAD+ may also be a potential cancer therapeutic, as it’s present in the salvage pathway of cancer cells and their metabolism.

Published Science Articles & References

NAD+ Reference (increasing energy, reducing free radicals, anti-ageing)

 

Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, and Swanson RA. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30: 2967–2978, 2010 [ PMC free article] [ PubMed] [ Google Scholar]

Benfeitas R, Uhlen M, Nielsen J, and Mardinoglu A. New challenges to study heterogeneity in cancer redox metabolism. Front Cell Dev Biol 5: 65, 2017 [ PMC free article] [ PubMed] [ Google Scholar]

Braidy N, Guillemin G, and Grant R. Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res 13: 173–184, 2008 [ PubMed] [ Google Scholar]

Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Guillemin GJ, Smythe G, and Sachdev P. Mapping NAD(+) metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence. Biogerontology 15: 177–198, 2014 [ PubMed] [ Google Scholar]

Godoy JA, Rios JA, Zolezzi JM, Braidy N, and Inestrosa NC. Signaling pathway cross talk in Alzheimer's disease. Cell Commun Signal 12: 23, 2014 [ PMC free article] [ PubMed] [ Google Scholar]

Godoy JA, Zolezzi JM, Braidy N, and Inestrosa NC. Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol Neurobiol 50: 744–756, 2014 [ PubMed] [ Google Scholar]

Marohnic CC, Bewley MC, and Barber MJ. Engineering and characterization of a NADPH-utilizing cytochrome b5 reductase. Biochemistry 42: 11170–11182, 2003 [ PubMed] [ Google Scholar]

Massudi H, Grant R, Guillemin GJ, and Braidy N. NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Redox Rep 17: 28–46, 2012 [ PMC free article] [ PubMed] [ Google Scholar]

Spaans SK, Weusthuis RA, van der Oost J, and Kengen SW. NADPH-generating systems in bacteria and archaea. Front Microbiol 6: 742, 2015 [ PMC free article] [ PubMed] [ Google Scholar]

Tang KS, Suh SW, Alano CC, Shao Z, Hunt WT, Swanson RA, and Anderson CM. Astrocytic poly(ADP-ribose) polymerase-1 activation leads to bioenergetic depletion and inhibition of glutamate uptake capacity. Glia 58: 446–457, 2010 [ PubMed] [ Google Scholar]

Tao R, Kim SH, Honbo N, Karliner JS, and Alano CC. Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56: 659–668, 2010 [ PMC free article] [ PubMed] [ Google Scholar]

Warburg O. and Christian W. Pyridine, the hydrogen transferring element of fermentation enzymes (Pyridine-nucleotide.). Biochemische Zeitschrift 287: 291–328, 1936 [ Google Scholar]

Yin F, Boveris A, and Cadenas E. Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid Redox Signal 20: 353–371, 2014 [ PMC free article] [ PubMed] [ Google Scholar]

Zeng J, Libien J, Shaik F, Wolk J, and Hernandez AI. Nucleolar PARP-1 expression is decreased in Alzheimer's disease: consequences for epigenetic regulation of rDNA and cognition. Neural Plast 2016: 8987928, 2016 [ PMC free article] [ PubMed] [ Google Scholar]

 

Clinical applications (in neurodegenerative diseases, cardiovascular risk factors, inflammatory conditions, hypoxic/chemotoxic damages, mental health)

 

Abeti R. and Duchen MR. Activation of PARP by oxidative stress induced by beta-amyloid: implications for Alzheimer's disease. Neurochem Res 37: 2589–2596, 2012 [ PubMed] [ Google Scholar]

Balu M, Mazhar A, Hayakawa CK, Mittal R, Krasieva TB, Konig K, Venugopalan V, and Tromberg BJ. In vivo multiphoton NADH fluorescence reveals depth-dependent keratinocyte metabolism in human skin. Biophys J 104: 258–267, 2013 [ PMC free article] [ PubMed] [ Google Scholar]

Braidy N, Grant R, Adams S, and Guillemin GJ. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 277: 368–382, 2010 [ PubMed] [ Google Scholar]

Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, and De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3: e2267, 2008 [ PMC free article] [ PubMed] [ Google Scholar]

Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, and Auwerx J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15: 838–847, 2012 [ PMC free article] [ PubMed] [ Google Scholar]

Diamond MP, Fletcher NM, Neubauer BR, Saed MG, H M AS, and Saed GM. Hypoxia-induced genotype switch in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase through the up-regulation of cytidine deaminase regulates postoperative adhesion development. J Minim Invasive Gynecol 22: S159, 2015 [ PubMed] [ Google Scholar]

Gensler HL. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr Cancer 29: 157–162, 1997 [ PubMed] [ Google Scholar]

Grant RS. and Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 70: 1759–1763, 1998 [ PubMed] [ Google Scholar]

Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18: 415–420, 2007 [ PubMed] [ Google Scholar]

Hershberger KA, Martin AS, and Hirschey MD. Role of NAD(+) and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol 13: 213–225, 2017 [ PMC free article] [ PubMed] [ Google Scholar]

Lehmann S, Costa AC, Celardo I, Loh SH, and Martins LM. PARP mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell Death Dis 7: e2166, 2016 [ PMC free article] [ PubMed] [ Google Scholar]

Martire S, Fuso A, Mosca L, Forte E, Correani V, Fontana M, Scarpa S, Maras B, and d'Erme M. Bioenergetic impairment in animal and cellular models of Alzheimer's disease: PARP-1 inhibition rescues metabolic dysfunctions. J Alzheimers Dis 54: 307–324, 2016 [ PubMed] [ Google Scholar]

Martire S, Mosca L, and d'Erme M. PARP-1 involvement in neurodegeneration: a focus on Alzheimer's and Parkinson's diseases. Mech Ageing Dev 146–148: 53–64, 2015 [ PubMed] [ Google Scholar]

Oblong JE. The evolving role of the NAD+/nicotinamide metabolome in skin homeostasis, cellular bioenergetics, and aging. DNA Repair (Amst) 23: 59–63, 2014 [ PubMed] [ Google Scholar]

Shetty PK, Galeffi F, and Turner DA. Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia. Neurobiol Dis 62: 469–478, 2014 [ PMC free article] [ PubMed] [ Google Scholar]

Shi H, Sun N, Mayevsky A, Zhang Z, and Luo Q. Preclinical evidence of mitochondrial nicotinamide adenine dinucleotide as an effective alarm parameter under hypoxia. J Biomed Opt 19: 17005, 2014 [ PubMed] [ Google Scholar]

Soudijn W, van Wijngaarden I, and Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27: 417–433, 2007 [ PubMed] [ Google Scholar]

Surjana D, Halliday GM, Martin AJ, Moloney FJ, and Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132: 1497–1500, 2012 [ PubMed] [ Google Scholar]

Tanno O, Ota Y, Kitamura N, Katsube T, and Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 143: 524–531, 2000 [ PubMed] [ Google Scholar]

Tong DL, Zhang DX, Xiang F, Teng M, Jiang XP, Hou JM, Zhang Q, and Huang YS. Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress. Pharmacology 90: 11–18, 2012 [ PubMed] [ Google Scholar]

Turunc Bayrakdar E, Uyanikgil Y, Kanit L, Koylu E, and Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1–42)-induced rat model of Alzheimer's disease. Free Radic Res 48: 146–158, 2014 [ PubMed] [ Google Scholar]

Vaccari CS, Nagamia S, Thoenes M, Oguchi A, Hammoud R, and Khan BV. Efficacy of controlled-release niacin in treatment of metabolic syndrome: correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. J Clin Lipidol 1: 605–613, 2007 [ PubMed] [ Google Scholar]

Wang H, Liang X, Luo G, Ding M, and Liang Q. Protection effect of nicotinamide on cardiomyoblast hypoxia/re-oxygenation injury: study of cellular mitochondrial metabolism. Mol Biosyst 12: 2257–2264, 2016 [ PubMed] [ Google Scholar]

Wang P, Du H, Zhang RY, Guan YF, Xu TY, Xu QY, Su DF, and Miao CY. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci 60: 317–324, 2010 [ PubMed] [ Google Scholar]

Wang P. and Miao CY. NAMPT as a therapeutic target against stroke. Trends Pharmacol Sci 36: 891–905, 2015 [ PubMed] [ Google Scholar]

Wang X, Hu X, Yang Y, Takata T, and Sakurai T. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res 1643: 1–9, 2016 [ PubMed] [ Google Scholar]

Wei CC, Kong YY, Li GQ, Guan YF, Wang P, and Miao CY. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci Rep 7: 717, 2017 [ PMC free article] [ PubMed] [ Google Scholar]

NADclinic Ltd © 2022 | Company Number: 11468735 | Medical Director Prof. Dr. Med. P. Shoettle GMC Reg - 7622265